WO2012033352A3 - 말과동물 양수 유래 다분화능 줄기세포 및 그 제조방법 - Google Patents

말과동물 양수 유래 다분화능 줄기세포 및 그 제조방법 Download PDF

Info

Publication number
WO2012033352A3
WO2012033352A3 PCT/KR2011/006637 KR2011006637W WO2012033352A3 WO 2012033352 A3 WO2012033352 A3 WO 2012033352A3 KR 2011006637 W KR2011006637 W KR 2011006637W WO 2012033352 A3 WO2012033352 A3 WO 2012033352A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
amniotic fluid
equine
multipotent stem
fluid derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/006637
Other languages
English (en)
French (fr)
Other versions
WO2012033352A2 (ko
Inventor
강경선
서민수
박상범
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KANG STEM HOLDINGS CO Ltd
Original Assignee
KANG STEM HOLDINGS CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KANG STEM HOLDINGS CO Ltd filed Critical KANG STEM HOLDINGS CO Ltd
Priority to US13/821,303 priority Critical patent/US9290739B2/en
Priority to EP11823785.8A priority patent/EP2615166B1/en
Priority to JP2013528119A priority patent/JP5833126B2/ja
Publication of WO2012033352A2 publication Critical patent/WO2012033352A2/ko
Publication of WO2012033352A3 publication Critical patent/WO2012033352A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 말과동물 양수 유래 다분화능 줄기세포 (equine amniotic fluid-derived multipotent stem cells;eAF-MSCs) 및 그의 제조방법에 관한 것으로, 보다 상세하게는, CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P 및 CD200에 대하여 모두 음성의 면역학적 특성을 나타내고, CD44, CD90 및 CD105에 대하여 모두 양성의 면역학적 특성을 나타내며, 외배엽, 중배엽 또는 내배엽 유래 세포로 분화하는 능력을 가지는, 말과동물 양수 유래 다분화능 줄기세포에 관한 것이다. 본 발명에 따르면, 말과동물의 양수가 말과동물 성체 다분화능 줄기세포의 공급원이 될 수 있음을 확인하였고, 제조된 말과동물 양수 유래 다분화능 줄기세포는 우수한 증식능 및 분화능을 나타내는 바, 줄기세포가 대량으로 요구되는 말과동물의 세포 치료제의 유효성분으로 사용될 수 있으며, 특히 성장능 및 분화능이 뛰어난 본 발명의 줄기세포는 경주마 등의 뼈, 힘줄, 근육 부상 및 결실 질환의 치료에 유용하다.
PCT/KR2011/006637 2010-09-08 2011-09-07 말과동물 양수 유래 다분화능 줄기세포 및 그 제조방법 Ceased WO2012033352A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/821,303 US9290739B2 (en) 2010-09-08 2011-09-07 Equine amniotic fluid-derived multipotent stem cells and a method for producing the same
EP11823785.8A EP2615166B1 (en) 2010-09-08 2011-09-07 Equine amniotic fluid derived multipotent stem cells and a production method therefor
JP2013528119A JP5833126B2 (ja) 2010-09-08 2011-09-07 ウマ科動物の羊水由来の多分化能幹細胞及びそれを製造する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100088144 2010-09-08
KR10-2010-0088144 2010-09-08

Publications (2)

Publication Number Publication Date
WO2012033352A2 WO2012033352A2 (ko) 2012-03-15
WO2012033352A3 true WO2012033352A3 (ko) 2012-06-28

Family

ID=45811084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/006637 Ceased WO2012033352A2 (ko) 2010-09-08 2011-09-07 말과동물 양수 유래 다분화능 줄기세포 및 그 제조방법

Country Status (5)

Country Link
US (1) US9290739B2 (ko)
EP (1) EP2615166B1 (ko)
JP (1) JP5833126B2 (ko)
KR (1) KR101380561B1 (ko)
WO (1) WO2012033352A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3060670B1 (en) 2013-10-24 2019-07-10 Ospedale San Raffaele S.r.l. Method
JP6373444B1 (ja) * 2017-05-10 2018-08-15 株式会社ホルス 羊膜由来原料の製造方法、化粧品の製造方法及び健康食品の製造方法
KR102092073B1 (ko) * 2019-07-26 2020-03-23 주식회사 엠케이바이오텍 말과 동물 양수 유래 줄기세포 및 이를 함유하는 근골격계 재생용 세포 치료제
KR102226542B1 (ko) * 2020-03-13 2021-03-11 주식회사 엠케이바이오텍 말과 동물 양수 유래 줄기세포 및 이를 함유하는 근골격계 재생용 세포 치료제
EP3909593A1 (en) 2020-05-15 2021-11-17 Rigshospitalet Stem cells for treating skin lesions
CN115161268B (zh) * 2021-03-19 2024-09-27 高雄医学大学 区域分层的软骨细胞层片的制备方法及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100950195B1 (ko) * 2009-03-20 2010-03-29 서울대학교산학협력단 Ｚｎｆ281을 발현하는 제대혈 유래 만능 줄기세포의 분리방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100950195B1 (ko) * 2009-03-20 2010-03-29 서울대학교산학협력단 Ｚｎｆ281을 발현하는 제대혈 유래 만능 줄기세포의 분리방법

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DE MATTOS CARVALHO, A. ET AL.: "Isolation and immunophenotypic characterization of mesenchymal stem cells derived from equine species adipose tissue", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 132, 2009, pages 303 - 306, XP026763874 *
KOCH, T.G. ET AL.: "Isolation of mesenchymal stem cells from equine umbilical cord blood", BMC BIOTECHNOLOGY, vol. 7, no. 26, 30 May 2007 (2007-05-30), pages 1 - 9, XP008156035 *
PARK, S-B. ET AL.: "Isolation and characterization of equine amniotic fluid-derived multipotent stem cells", CYTOTHERAPY, vol. 13, 2011, pages 341 - 349, XP055094993 *
TSAI, M-S. ET AL.: "Isolation of human multipotent mesenchymal stem cells from second- trimester amniotic fluid using a novel two-stage culture protocol", HUMAN REPRODUCTION, vol. 19, no. 6, 2004, pages 1450 - 1456, XP002404972 *

Also Published As

Publication number Publication date
KR101380561B1 (ko) 2014-04-02
WO2012033352A2 (ko) 2012-03-15
EP2615166A4 (en) 2014-03-05
US20130230924A1 (en) 2013-09-05
EP2615166A2 (en) 2013-07-17
JP5833126B2 (ja) 2015-12-16
KR20120026014A (ko) 2012-03-16
EP2615166B1 (en) 2018-08-15
JP2013541329A (ja) 2013-11-14
US9290739B2 (en) 2016-03-22

Similar Documents

Publication Publication Date Title
WO2012033352A3 (ko) 말과동물 양수 유래 다분화능 줄기세포 및 그 제조방법
HK1256130A1 (zh) 用於嵌合抗原受体和其他受体的表达的t细胞
WO2014011881A3 (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
JP2014000094A5 (ja) 臍帯由来細胞を用いた局部的または散在的脳外傷の改善
PH12014501175A1 (en) Medium composition for rejuvenating stem cells
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
AR084754A1 (es) Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
WO2016011210A3 (en) Engineered cells for adoptive cell therapy
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
NZ591146A (en) Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
PH12013500389A1 (en) Differentiation of human embryonic stem cells
WO2011027085A3 (fr) Principe actif issu de candida saitoana et utilisation cosmetique pour la detoxification des cellules de la peau
NZ595987A (en) A novel formulation of diclofenac
JP2015159895A5 (ko)
NZ595903A (en) A novel formulation of metaxalone
MY168748A (en) Anti-asic1 antibodies and uses thereof
HK1249029A1 (zh) 表达pd-l1的造血干细胞及其用途
MY196026A (en) Stem Cell Conditioned Media for Clinical and Cosmetic Applications
WO2014028668A3 (en) Stem cell enhancing therapeutics
NZ722319A (en) A novel formulation of meloxicam
MX2015006268A (es) Diferenciacion de las celulas de fibroblastos humanos.
CA2904533C (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
MX2013008046A (es) Hidrogeles a base de esteres de acido poliisobutenosuccinico.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11823785

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013528119

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011823785

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13821303

Country of ref document: US